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ABSTRACT
RNA interference (RNAi) by means of short hairpin
RNA (shRNA) has developed into a powerful tool for
loss-of-function analysis in mammalian cells. The
principal problem in RNAi experiments is off-target
effects, and the most vigorous demonstration of
the specificity of shRNA is the rescue of the RNAi
effects with a shRNA-resistant target gene.
This presents its own problems, including the
unpredictable relative expression of shRNA and
rescue cDNA in individual cells, and the difficulty
in generating stable cell lines. In this report, we
evaluated the plausibility of combining the expres-
sion of shRNA and rescue cDNA in the same vector.
In addition to facilitate the validation of shRNA
specificity, this system also considerably simplifies
the generation of shRNA-expressing cell lines.
Since the compensatory cDNA is under the control
of an inducible promoter, stable shRNA-expressing
cells can be generated before the knockdown
phenotypes are studied by conditionally turning off
the rescue protein. Conversely, the rescue protein
can be activated after the endogenous protein is
completely repressed. This approach is particularly
suitable when prolonged expression of either the
shRNA or the compensatory cDNA is detrimental
to cell growth. This system allows a convenient
one-step validation of shRNA and generation of
stable shRNA-expressing cells.
INTRODUCTION
RNA interference (RNAi) is an evolutionarily conserved
gene-silencing process triggered by double-stranded
RNAs (dsRNAs) (1). The use of RNAi as a technique
for analyzing loss-of-function phenotypes has revolution-
ized research in mammalian cells. One way to induce
RNAi in mammalian cells is by transfection of synthetic
small interfering RNAs (siRNAs). These siRNAs are
19-base-pair (bp) dsRNA with 2-nucleotide (nt) 30 over-
hangs (2), and mimic the structure of microRNA
(miRNA) intermediates of the natural processing of
longer dsRNA by RNase III. One strand of the siRNA
or miRNA duplexes (called guide strand) is incorporated
into the RNA-induced silencing complex (RISC), where
it directs RISC to bind to complementary mRNA. It is
believed that the other strand of the siRNA or miRNA
(called passenger strand) is not incorporated into RISC
and is destroyed. RISC cleaves the mRNAs at a site 10nt
upstream of the nucleotide complementing the 50—most
nucleotide of the guide strand, and the mRNA fragments
are degraded by other nucleases, resulting in knockdown
of expression (3).
An alternative way to induce RNAi in mammalian cells
is by expression plasmids or viral vectors. A common
approach involves the transcription by RNA polymerase
III of short hairpin RNAs (shRNA). The shRNAs consist
of a stem of 19–29bp linked by a small terminal loop
(4–6). The prevailing view is that shRNAs mimic the
structure of a miRNA intermediate generated by the
RNase III enzyme Drosha. Another RNase III enzyme
called Dicer acts on the shRNAs to produce siRNA/
miRNA duplexes, which are then loaded onto RISC to
mediate silencing (7).
The use of shRNA oﬀers several important advantages
over siRNA (8). First, more delivery options are available
for shRNA, including transfection, electroporation and
infection with viral vectors. Second, substantially lower
cost is required to generate shRNA than siRNA.
Furthermore, while silencing using siRNA is inevitably
transient, shRNA-expressing constructs can be stably
integrated into the genome. Finally, while the eﬀects of
siRNA after delivery is constitutive, both constitutive and
inducible systems can be used for shRNA after delivery.
It is generally accepted that the major problem of using
shRNAs (as well as siRNAs) in experimentation is the
possibility of oﬀ-target eﬀects (9,10). Several methods are
utilized to conﬁrm the speciﬁcity of the RNAi results,
including the use of shRNAs against irrelevant targets
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However, the ultimate control for shRNA experiment is
the rescue of the RNAi eﬀects by the expression of the
target gene in a form refractory to the shRNA (11,12).
This is usually achieved by introducing one or more silent
point mutations to the region of the cDNA that is targeted
by the shRNA.
The rescue of RNAi phenotypes using shRNA-resistant
cDNA itself may present several problems. It is likely that
individual cells may take up diﬀerent amount of shRNA-
versus cDNA-expressing constructs, triggering a spectrum
of phenotypes within a population. Moreover, it is not
trivial to obtain stable expression of both shRNA and
cDNA at the same time. Here we describe a solution to the
problems using a system that expresses both the shRNA
and the rescue cDNA from the same plasmid. As the
cDNA is under the control of an inducible promoter, the
eﬀects of the gene knockdown are eﬀectively under
conditional control. This considerably simpliﬁes the
generation of stable cell lines when prolonged expression
of either the shRNA or the compensatory cDNA is
detrimental to cell growth. The eﬀectiveness of the pKAR
system is demonstrated with cyclin A and MAD2.
MATERIALS AND METHODS
Materials
All reagents were obtained from Sigma-Aldrich (St. Louis,
MO, USA) unless stated otherwise.
DNA constructs
pKAR1 was based on pUHD-P1/3C (13), which was in
turn based on the tetracycline-inducible system
pUHD10-3 (14) (a gift from Dr Hermann Bujard,
University of Heidelberg, Germany), and mU6pro (5)
(a gift from Dr David Turner, University of Michigan,
MI, USA). The BamHI - BamH I fragment was ﬁrst
removed from pUHD-P1/3C. The resulting plasmid was
cut with Hind III-Pvu II, and inserted with the Hind III-
Pvu II fragment from mU6pro. Bbs I sites were then
destroyed by mutagenesis using the oligonucleotides
50CCCTTTCGTCTTTAGTCGAGTTT30,5 0CATAGAA
GAGACCGGGACC30 and 50GAGGCGAAGCTTCG
GGCGGC30 (and their antisense). Mutation of the Bbs I
site in the CMV promoter did not aﬀect expression (our
unpublished data). Speciﬁc shRNA constructs were
created by annealing the following pairs of primers into
Bbs I-Xba I of mU6pro or pKAR1: 50TTTGGTAGCA
GAGTTTGTGTACATTCAAGAGATGTACACAAA
CTCTGCTACTTTTT30 and 50CTAGAAAAAGTAGC
AGAGTTTGTGTACATCTCTTGAATGTACACAAA
CTCTGCTAC30 (corresponded to positions 823–841 of
human cyclin A2 ORF); 50TTTGGAGTCGGGACCA
CAGTTTATTCAAGAGATAAACTGTGGTCCCGAC
TCTTTTT30 and 50CTAGAAAAAGAGTCGGGACCA
CAGTTTATCTCTTGAATAAACTGTGGTCCCGAC
TC30 (corresponded to positions 505–523 of human
MAD2 ORF). Site-directed mutagenesis was carried out
with QuickChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA). Plasmids expressing
FLAG-tagged cyclin A (15), GST-3C protease (13) and
histone H2B-GFP (16) were constructed or obtained from
sources as previously described. Cyclin A resistant to the
shRNA was created by introducing silent mutations using
the oligonucleotide 50CCAGAAGTAGCGGAATTCGTC
TACATTACAGA30 and its antisense. The cyclin A
shRNA (in mU6pro) was ligated into this plasmid using
the Hind III-Pvu II sites to create FLAG-cyclin A/shRNA
in pKAR1. The BamH I fragment containing the
puromycin-resistant gene (a gift from Katsumi
Yamashita, Kanazawa University, Japan) was put into
BamH I-cut FLAG-cyclin A/shRNA in pKAR1 to
generate FLAG-cyclin A/shRNA in pKAR1/PUR.
MAD2 in CMV5 was a gift from Robert Benezra
(Memorial Sloan-Kettering Cancer Center, NY, USA).
The Nco I fragment was ligated into pUHD-P2 (15) to
generate HA-MAD2 in pUHD-P2. Silence mutations were
introduced using 50GAGTCAGGTCCTCAGTTTA30
(and its antisense) to create a shRNA-resistant MAD2.
The MAD2 shRNA (in mU6pro) was ligated into this
plasmid using the Hind III-Pvu II sites to create HA-
MAD2/shRNA in pKAR1.
Cell culture
HtTA1 cells are HeLa cells (human cervical carcinoma)
expressing the tTA tetracycline repressor chimera (15).
Cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% (v/v) calf serum
(Invitrogen Life Technologies, Carlsbad, CA, USA) in a
humidiﬁed incubator at 378Ci n5 %C O 2. Unless stated
otherwise, cells were treated with the following reagents at
the indicated ﬁnal concentration: blasticidin (5mg/ml),
doxycycline (2mg/ml), nocodazole (0.1mg/ml), and puro-
mycin (1mg/ml). Cells were transfected with the calcium
phosphate precipitation method (17). Cell-free extracts
were prepared as previously described (18). For transient
expression of shRNA-expressing plasmids, a plasmid
expressing histone H2B-GFP and a blasticidine-resistant
gene was cotransfected and cells were grown in a medium
containing the blasticidin for 36h to enrich the transfected
cells. Selection medium was washed out and the cells were
grown in normal medium for another 12h. For generation
of stable cell lines, cells were transfected with FLAG-
cyclin A/shRNA in pKAR1/PUR and grown in the
medium containing puromycin. After about two weeks
of selection, individual colonies were isolated and
propagated in the absence of puromycin. Individual
clones were either mock-treated or exposed to doxycycline
for 48h before cell-free extracts were prepared. The
knockdown of endogenous cyclin A and the inducible
expression of FLAG-cyclin A were evaluated by immuno-
blotting for cyclin A.
Flow cytometry
Cells were trypsinized and washed with phosphate-
buﬀered saline (PBS). The cells were then ﬁxed in
ice-cold 80% ethanol and stained with a solution contain-
ing 40mg/ml propidium iodide and 40mg/ml RNaseA at
378C for 30min. Cell cycle distribution (for 10000 cells)
was analyzed using a FACSort machine (Becton–
Dickinson). For bivariate analysis of DNA content and
cyclin A expression, cells were harvested by trypsinization,
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resuspended in ice-cold MeOH for 10min. The cell
pellet was washed twice with PBST (PBSþ0.5%
Tweenþ0.05%w/v BSA), resuspended in the residue
buﬀer, and incubated with 1mg of monoclonal
antibody E23at 258C for 60min. The cells were washed
twice with PBST, resuspended in the residue buﬀer,
and incubated with 2.5ml of FITC-conjugated rabbit
anti-mouse IgG (DAKO, Glostrup, Denmark) at 258C for
60min. After washed twice in PBST, the cells were
processed for propidium iodide staining and ﬂow
cytometry.
Antibodies and immunological methods
Monoclonal antibodies A17 against CDC2 (19), E23
against cyclin A2 (20), and M2 against FLAG tag (21)
were obtained from sources as previously described.
Monoclonal antibody V152 against cyclin B1 was a gift
from Dr Julian Gannon and Dr Tim Hunt (Cancer
Research UK, UK). Monoclonal antibody against MAD2
was obtained from BD Biosciences Pharmingen (Franklin
Lakes, NJ, USA). Immunoblotting was performed as
previously described (18).
RESULTS AND DISCUSSION
We constructed the pKAR (Knockdown And Rescue)
plasmids based on an inducible system designed by
Hermann Bujard’s group (14), and a shRNA-expressing
system originated from David Turner’s group (5)
(Figure 1A). The shRNA was expressed from a mouse
U6 RNA promoter, and the rescue cDNA was expressed
under the control of doxycycline. The cDNA expressed
from pKAR1 was engineered to fuse at the N-terminus
with a FLAG-tag and a 3C protease cleavage site
(Figure 1B). Due to the slight increase in size conferred
by the epitope tag, both the endogenous protein to be
silenced and the ectopically expressed version can be
detected simultaneously. The tag also allowed the
recombinant protein to be speciﬁcally detected or immu-
noprecipitated. Furthermore, the epitope tag can be
removed using 3C proteases.
To evaluate if the pKAR system works in principal, we
put it to test by targeting two genes: cyclin A and MAD2.
Cyclin A plays critical roles in S phase and mitosis (22),
and MAD2 is an essential component of the spindle-
assembly checkpoint (23). Oligonucleotides designed to
express shRNAs against these genes were put behind the
U6 promoter. The rescue MAD2 and cyclin A cDNAs
were subcloned under the control of tetracycline response
element (TRE) (Figure 2A). Silence mutations were
introduced into the regions that are targeted by the
shRNAs, rendering their mRNAs to be resistant to the
knockdown (Figure 2B). In this study, HeLa cells
expressing the tTA tetracycline repressor chimera were
used, so that the expression of the rescue cDNAs was
repressed in the presence of doxycycline.
To determine if the endogenous cyclin A could be
downregulated by the cyclin A/shRNA construct, cells
were transfected with either control vectors or the cyclin
A/shRNA construct. Figure 3A shows that the expression
of cyclin A was eﬀectively attenuated by the shRNA
(lanes 1 and 2). As expected, FLAG-cyclin A (which
exhibited a slightly slower gel mobility than the endoge-
nous cyclin A) was expressed in the absence, but not the
ATGGACTACAAAGACGATGACGATAAAGCCATGCTGGAAGTTCTGTTTCAGGGGCCCATGGCTCGAGAATTCGAGCTCGGTACCCGGGGATCC
M  D  Y  K  D  D  D  D  K  A  M  L  E  V  L  F  Q  G  P  M
FLAG-tag 3C protease site
Nco I EcoR I BamH I
GCTAGCCACA
Nhe I
pKAR1
(4.6 kb)
Ampr ColE1 ori
SV40 pA TRE-PminCMV PU6
MCS Xba I Bbs I
A
B
FLAG-3C-
shRNA cDNA
Xho I Apa I
Figure 1. A vector for co-expression of shRNA and shRNA-resistant cDNA. (A) Schematic diagram of pKAR1. The various elements are shown to
scale: TRE, tetracycline response element; PminCMV, minimal immediate early cytomegalovirus (CMV) promoter; FLAG-3C-MCS, multiple cloning
sites; SV40 pA, SV40 polyadenylation signal; PU6, mouse U6 RNA promoter; Amp
r, ampicillin-resistant gene; ColE1 ori, ColE1 replication origin.
The shRNA is ﬁrst inserted between Bbs I-Xba I exactly as described for mU6pro (5), and the shRNA-resistant cDNA is cloned into the multiple
cloning sites (see panel B). (B) The cDNA cloning region of pKAR1. The protein sequence of the N-terminal tag is shown. After the cloning of the
shRNA, the cDNA can be inserted in frame into the unique Apa I, Nco I, Xho I, EcoR I and BamH I sites. Un-tagged version can be cloned using
the Nhe I site. The FLAG-tag is highlighted, the 3C protease recognition sequence is underlined, and the arrow indicates the site of cleavage.
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recombinant FLAG-cyclin A was also conﬁrmed by
immunoblotting for FLAG. Figure 3B shows that
FLAG-cyclin A was suppressed by doxycycline pro-
gressively over the time course of the experiment. These
results indicate that while the endogenous cyclin A could
be silenced by the shRNA, the co-expressed recombinant
cyclin A was refractory to the knockdown.
To further verify the versatility of the pKAR system, we
performed the converse experiment by turning on the
rescue cDNA after the endogenous protein was knock-
down by the shRNA. Cells were transfected with MAD2/
shRNA in pKAR1 in the presence of doxycycline
to repress the expression of the recombinant MAD2.
Figure 3C shows that the endogenous MAD2 was
eﬀectively knockdown by the procedure (lanes 1 and 2).
Furthermore, the shRNA-resistant MAD2 (slightly larger
than the endogenous protein because of the epitope tag)
was induced robustly after the removal of doxycycline
in the medium. Taken together, these data demonstrate
that the rescue cDNAs could either be turned on or oﬀ
after the endogenous proteins were silenced.
To generate cell lines that stably express cyclin A
shRNA and the corresponding rescue cDNA, a puro-
mycin-resistant gene was engineered into the cyclin
A/shRNA construct (Figure 2). Cells were transfected
and selected in medium containing puromycin and in the
absence of doxycycline. The basis of this was that the
downregulation of cyclin A without a compensatory
expression of the shRNA-resistant cyclin A would be
cytotoxic. After selection, individual colonies were iso-
lated and the knockdown of the endogenous cyclin A and
the expression of the recombinant cyclin A were analyzed
(Figure 4). We were able to generate cell lines that
expressed FLAG-cyclin A, but were deﬁcient in the
expression of endogenous cyclin A. We also conﬁrmed
that the FLAG-cyclin A expression could be switched oﬀ
with doxycycline.
To determine if ﬁne adjustment of cyclin A expression
can be achieved in the stable cell lines, cells were treated
with diﬀerent concentrations of doxycycline before
harvested. Figure 5A shows that a range of cyclin
A expression, from an undetectable level to a highly
overexpressed level, was obtained by varying the doxycy-
cline concentration. The expression of FLAG-cyclin A
could be turned oﬀ relatively rapidly (Figure 5B). Our
conclusion is that while the method is rather robust, the
precise dose and time of doxycycline adopted for ﬁne
adjustment of the rescue protein will have to be
determined empirically (which depends on the half-life of
the protein and its levels relative to the endogenous
protein).
TRE-PminCMV shRNA SV40 pA PU6
Cyclin A
Puromycinr
TRE-PminCMV shRNA SV40 pA PU6
Cyclin A
TRE-PminCMV shRNA SV40 pA PU6
MAD2
Cyclin A/shRNA in pKAR1
MAD2/shRNA in pKAR1
Cyclin A/shRNA in pKAR1/PUR
A
B
GTAGCAGAGTTTGTGTACA
G  A  C  C
823 841
Cyclin A
GAGTCGGGACCACAGTTTA
A  T  T
505 523
MAD2
Figure 2. Schematic diagrams of constructs used in this study. (A) Plasmids containing MAD2 shRNA, cyclin A shRNA, shRNA-resistant MAD2,
and shRNA-resistant cyclin A were constructed as indicated. A puromycin-resistant gene (which contained its own SV40 early promoter and SV40
polyadenylation signal) was also inserted into the cyclin A/shRNA construct. The various elements are shown to scale, and only a part of vector is
shown (compare Figure 1). (B) The shRNA-targeted sequences and the silence mutations of MAD2 and cyclin A. The sequences in human MAD2
and cyclin A that are targeted by the shRNAs are shown. The numbers correspond to the nt positions in the open reading frames. The bases that
were changed in generating the silent mutations are indicated below the sequences.
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level when both the endogenous and the rescue cyclin A
were repressed, it is conceivable that a minor portion of
cells still expressed high levels of cyclin A. To examine this
possibility, the abundance of cyclin A in individual cells
was determined with ﬂow cytometry. Several lines of
evidence indicate that cyclin A is actively degraded
during mitosis and G1 phase (24). In agreement with
this, two populations of cells with diﬀerent cyclin
A levels were detected with ﬂow cytometry (Figure 6A).
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Figure 3. Knockdown and rescue by transient transfection of pKAR1
constructs. (A) Knockdown of endogenous cyclin A and expression of
recombinant cyclin A by transient transfection. HtTA1 cells were
transfected with either control vectors or cyclin A/shRNA-expressing
plasmids. After enriching the transfected cells (Materials and Methods),
over 90% of cells expressed a cotransfected GFP-tagged histone H2B
(data not shown). Cells expressing cyclin A and shRNA were either
mock-treated or treated with doxycycline for 48h as indicated. Cell-free
extracts were prepared and subjected to immunoblotting for cyclin A
and FLAG. Uniform loading of lysates was conﬁrmed by immunoblot-
ting for CDC2. (B) Suppression of recombinant cyclin A expression by
doxycycline. Cells were transfected with cyclin A/shRNA in pKAR1 as
described in panel A. After doxycycline was applied, cell-free extracts
were prepared at the indicated time points and subjected to
immunoblotting for cyclin A. Lysates from control cells were loaded
in lane 1. The lower band in lane 2 probably is a degradative product
of FLAG-cyclin A. (C) Knockdown and rescue of MAD2. HtTA1 cells
were transfected with either control vectors (lane 1) or MAD2/shRNA-
expressing plasmids in the presence of doxycycline. After enriching the
transfected cells, the MAD2- and shRNA-expressing cells were washed
and grown in doxycycline-free medium. At the indicated time points,
cell-free extracts were prepared and subjected to immunoblotting for
MAD2.
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Figure 5. Regulation of cyclin A expression in stable cyclin A/shRNA-
expressing cells. (A) Dose-dependent repression of cyclin A by
doxycycline in stable cyclin A/shRNA-expressing cells. A cyclin
A/shRNA-stable cell line (clone 11) was treated with diﬀerent
doses of doxycycline (from lanes 2–11: 1.3, 2.6, 3.3, 4.4, 6.6, 13.3, 40,
400 and 2000ng/ml) for 48h. Cell-free extracts were prepared and the
expression of cyclin A was detected by immunoblotting. Extracts from
control cells were loaded in lane 1 and CDC2 analysis was included to
assess protein loading and transfer. (B) Time-dependent repression of
cyclin A by doxycycline in stable cyclin A/shRNA-expressing cells. A
cyclin A/shRNA-stable cell line (clone 3) was exposed to 2mg/ml of
doxycycline and harvested at the indicated time points. Cell-free
extracts were prepared and were subjected to immunoblotting for cyclin
A and cyclin B1. Extracts from control cells were loaded in lane 1
and uniform loading of lysates was conﬁrmed by immunoblotting
for CDC2.
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Figure 4. Knockdown and conditional rescue of cyclin A in stable cell
lines. HtTA1 cells were transfected with cyclin A/shRNA in pKAR1/
PUR and grown in puromycin-containing medium. After about two
weeks of selection, individual colonies were isolated and were
either mock-treated or treated with doxycycline for 48h. Cell-free
extracts were prepared and cyclin A was detected by immunoblotting.
Extracts from control cells and two representative clones were
loaded. Equal loading of lysates was conﬁrmed by immunoblotting
for CDC2.
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entire population, suggesting that cyclin A was not
only eliminated in selected cells. After staining with
propidium iodide, bivariate analysis further indicated
that cyclin A was reduced in diﬀerent phases of the cell
cycle (Figure 6B).
Cells expressing cyclin A shRNA and the compensatory
cDNA together displayed a relatively normal cell cycle
proﬁle (Figure 6C). In marked contrast, a prominent G2/M
delay was introduced after FLAG-cyclin A was repressed.
In agreement with this, cyclin B1 (which normally
accumulates during the G2 phase and mitosis) also
increased after the elimination of cyclin A (Figure 5B).
Detailed analysis of the cyclin A knockdown phenotypes
will be described elsewhere. This brief analysis serves to
illustrate that the cytostatic phenotypes from shRNA can
be conditionally rescued in stable cell lines, underscoring
the usefulness of the pKAR system.
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Figure 6. Manifestation of knockdown phenotypes after the removal of the rescue cyclin A or MAD2. (A) Cyclin A is silenced by shRNA in the
whole cell population. Stable cyclin A/shRNA-expressing cells (clone 3) were either mock-treated or treated with doxycycline for 48h. The cells were
then ﬁxed, stained with a monoclonal antibody against cyclin A, and processed for ﬂow cytometry analysis. The parental HtTA1 cells were also
analyzed as a control. (B) Cyclin A is repressed by shRNA throughout the cell cycle. Stable cyclin A/shRNA-expressing cells were either mock-
treated or exposed to doxycycline for 48h. The cells were then ﬁxed, stained with a monoclonal antibody against cyclin A and propidium iodide, and
subjected to bivariate ﬂow cytometry analysis. The parental HtTA1 cells were also analyzed as a control. The positions of the 2N and 4N DNA
contents are indicated. (C) Knockdown of cyclin A delays the cell cycle at G2/M. Stable cyclin A/shRNA-expressing cells were either mock-treated or
treated with doxycycline for 48h. The cells were then ﬁxed, stained with propidium iodide, and processed for ﬂow cytometry analysis. The parental
HtTA1 cells were also analyzed as a control. The positions of the 2N and 4N DNA contents are indicated. (D) Knockdown of MAD2 abolishes the
spindle-assembly checkpoint. Cells were transfected with MAD2/shRNA in pKAR1. Plasmids expressing GFP-histone H2B constitutionally were
cotransfected to allow the identiﬁcation of transfected cells. The cells treated with nocodazole, and were either mock-treated or treated with
doxycycline for 44h. The cells were then ﬁxed, stained with propidium iodide, and processed for ﬂow cytometry analysis of the GFP-positive cells.
The positions of the 2N, 4N and 8N DNA contents are indicated.
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knockdown and rescue, the spindle-assembly checkpoint
was analyzed after the knockdown of MAD2. Cells were
transfected with MAD2/shRNA in pKAR1 and the
expression of the compensatory MAD2 was either induced
or suppressed with doxycycline. As expected, cells
co-expressing MAD2 shRNA and the rescue MAD2
were blocked with 4N DNA contents after treatment
with the spindle-disrupting drug nocodazole (Figure 6D).
In marked contrast, cells expressing MAD2 shRNA
in the absence of compensatory MAD2 failed to be
arrested by nocodazole, and continue to re-replicate their
DNA. These data indicate that MAD2 knockdown
phenotypes could be conditionally rescued with the
pKAR system.
In summary, we have devised a vector that can express
shRNA and the respective rescue cDNA together. The
pKAR1 vector provides a convenient way to subclone
shRNA and the rescue cDNA, as well as for the generation
of stable cell lines. This system is particularly useful when
the prolonged expression of either the shRNA or the
compensatory cDNA is cytotoxic. In the ﬁrst scenario,
the shRNA can be allowed to completely knockdown the
endogenous proteins in the presence of the rescue cDNA;
the rescue cDNA can then be turned oﬀ to attain the
knockdown phenotypes. In the second scenario, the rescue
cDNA can be turned on only after the endogenous proteins
are completely eliminated. Here we have used a cell line
expressing the tTA tetracycline repressor chimera, so that
the expression of the rescue cDNA was repressed by
doxycycline. Likewise, cell lines expressing the reverse tTA
(25) can also be adopted to turn on the rescue cDNA with
doxycycline. Other applications of the method include the
conditional removal of the rescue protein for a deﬁned
period of time before the rescue protein is restored. We
found that the pKAR system is particularly suitable for
generation of stable cell lines. Probably due to the toxicity
of both cyclin A/shRNA and cDNA, we found that all the
colonies isolated were inevitably without endogenous cyclin
A and expressing FLAG-cyclin A. Furthermore, clones
that grew at a normal rate tended to express the rescue
cyclin A at a level similar to that in control cells (our
unpublished data). Thus this method appears to have an
additional advantage of isolating clones that express the
rescue protein at a comparable level to the endogenous
protein.
In conclusion, the pKAR system allows a convenient
one-step validation of shRNA and generation of stable
shRNA-expressing cells.
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